期刊
STEM CELLS AND DEVELOPMENT
卷 21, 期 17, 页码 3147-3151出版社
MARY ANN LIEBERT INC
DOI: 10.1089/scd.2012.0214
关键词
-
资金
- Cancer Society of Stockholm
- Children's Cancer Foundation
- Karolinska Institutet
- Stockholm City Council
- Swedish Cancer Society
- Swedish Research Council
- Swedish Society of Medicine
- Tobias Foundation
- VINNOVA
- German Research Foundation (DFG)
Mesenchymal stromal cells (MSCs) represent an attractive tool for cellular therapies on grounds of their immunomodulatory and regenerative properties. Here, we report the first case of familial hemophagocytic lymphohistiocytosis (FHL) treated with MSCs. This rare autosomal recessive disorder is characterized by hyperinflammation that results from a failure of natural control mechanisms to terminate immune responses. Crosstalk between innate (macrophages) and adaptive (T cells) immunity is heavily altered. Immuno-chemotherapy is only temporarily effective in the control of FHL, and the outcome is usually fatal unless the patient undergoes allogeneic stem cell transplantation. Our hypothesis was that the application of MSCs could be effective in the treatment of FHL, since MSCs possess a broad repertoire of immunomodulating mechanisms impacting both innate and adaptive immunity pathways. In fact, the adoptive transfer of third-party MSCs transiently controlled the extreme immunological deterioration in the described patient who was otherwise not responsive to standard treatment, including repetitive chemotherapy. If these transient effects of MSCs can be confirmed in future-controlled clinical trials, adoptive MSC therapy could represent a salvage agent in FHL acting as a bridge to definitive treatment with stem cell transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据